Welcome to our dedicated page for ProPhase Labs news (Ticker: PRPH), a resource for investors and traders seeking the latest updates and insights on ProPhase Labs stock.
ProPhase Labs, Inc. (PRPH) is a diversified natural health medical science company that specializes in providing a wide range of diagnostic and consumer products. The company's operations are divided into two primary segments: Diagnostic Services and Consumer Products.
The Diagnostic Services segment offers COVID-19 diagnostic testing to a broad range of customers across the United States, including health plans, third-party payers, and government organizations. This segment is focused on delivering timely and accurate diagnostic information, critical during the ongoing pandemic and beyond.
The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) healthcare products and dietary supplements within the United States. In addition to these offerings, ProPhase Labs also provides personal genomics products and services, enabling consumers to gain insights into their genetic makeup.
ProPhase Labs is committed to advancing health and wellness through innovative products and services. Recent achievements include the development of the BE-Smart Esophageal Cancer Test, leveraging the company's AI platform and extensive genomics database. This test represents a significant step forward in cancer diagnostics and showcases the company's commitment to leveraging advanced technologies for improved healthcare outcomes.
Moreover, ProPhase Labs has projects such as Project ZenQ-AI and Equivir, which underline the company's focus on continuous research and innovation. These initiatives highlight ProPhase Labs' role in pushing the boundaries of medical science and consumer health products.
Financially, ProPhase Labs maintains a solid position, with ongoing projects and partnerships further strengthening its market presence. The company actively communicates with its retail investors through multiple channels, ensuring transparency and engagement with its stakeholders.
For more information, visit ProPhase Labs.
ProPhase Labs, Inc. (NASDAQ: PRPH) will hold a conference call on May 13, 2022, at 11:00 a.m. ET to discuss first-quarter results for the period ending March 31, 2022. CEO Ted Karkus will lead the call, which will include a question-and-answer session. Participants can register via a provided link and will receive dial-in details upon registration. Toll-free dial-in is available at 1-866-777-2509 for U.S. callers, and international callers can use 1-412-317-5413. The conference call will be broadcast live and available for replay after it concludes.
ProPhase Labs, Inc. (NASDAQ: PRPH) announced that Chairman and CEO Ted Karkus will present a corporate overview at the Planet MicroCap Showcase 2022 on May 4, 2022, at 1:30 PM EST. The presentation will be accessible through a webcast link provided in the announcement.
ProPhase Labs focuses on diagnostics and genomics, offering services like whole genome sequencing and COVID-19 testing through its CLIA-certified laboratories. The company aims to expand its testing capabilities globally and continues to pursue strategic investments.
ProPhase Labs (NASDAQ: PRPH) reported strong financial results for the year ending December 31, 2021, with net revenue of $79 million, marking a 445% increase from the previous year. The company achieved a net income of $6.3 million or $0.41 per share, compared to a net loss of $2.1 million in 2020. The fourth quarter showcased net revenues of $45.2 million and a net income of $10.6 million. Adjusted EBITDA for 2021 was $18.1 million. ProPhase's new diagnostic services significantly drove growth, while strategic acquisitions and improved operational efficiencies indicate a promising outlook for 2022.
ProPhase Labs (NASDAQ: PRPH) announced a conference call on March 30, 2022, at 11:00 a.m. ET, to discuss the results for its fourth quarter and full year ending December 31, 2021. This call will be hosted by CEO Ted Karkus and include a Q&A session. A press release with detailed results will precede the call. Participants can register online to receive dial-in information, or call in directly using provided toll-free numbers.
ProPhase Labs offers diagnostic, genomics testing, and contract manufacturing services, with subsidiaries focusing on a range of healthcare solutions.
ProPhase Labs, Inc. (NASDAQ: PRPH) has declared a special cash dividend of $0.30 per share, payable on March 10, 2022, to stockholders of record as of March 1, 2022. This decision follows strong projected financial performance for Q4 2021 and the upcoming Q1 2022, with significant growth in net income and EBITDA. Chairman Ted Karkus emphasized a commitment to returning capital to shareholders while maintaining ample liquidity for future growth opportunities.
ProPhase Labs (Nasdaq: PRPH) announces that Chairman and CEO Ted Karkus will present at the MicroCap Rodeo Winter Wonderland Best Ideas Conference from February 8-11, 2022. His presentation is scheduled for February 9, 2022, at 12:00 PM ET.
Additionally, Karkus will be available for one-on-one investor meetings on February 10-11. ProPhase Labs focuses on biotech and genomics, providing testing services and genomics data for healthcare advancements.
ProPhase Labs (NASDAQ: PRPH) reports significant growth in PCR COVID-19 testing volumes, exceeding 300,000 tests in Q4 2021, a sharp increase from about 110,000 in Q1 2021. The rise is attributed to a growing customer base and the emergence of the Omicron variant. The company expanded its workforce, increasing lab personnel from 50 to over 250 to meet demand while maintaining average result turnaround times of under 48 hours. Looking ahead, ProPhase anticipates ongoing growth across its testing and genomic services throughout 2022.
ProPhase Labs (Nasdaq: PRPH) announces that CEO Ted Karkus will present a corporate overview at the H.C. Wainwright Bioconnect 2022 Virtual Conference, scheduled for January 10-13, 2022. The presentation will be available on-demand for registered attendees starting at 7:00 a.m. ET on January 10.
ProPhase Labs is a diversified biotech company focusing on genomics and CLIA lab services, including COVID-19 testing, whole genome sequencing, and genetic research.
ProPhase Labs (NASDAQ: PRPH) has appointed Sam A. Beeler as Chief Strategy Officer while promoting Alice Lioi and Jason Karkus to Executive Vice Presidents/Co-Chief Operating Officers, and Sergio Miralles to Executive Vice President/Chief Information Officer. CEO Ted Karkus highlighted Beeler's role in enhancing Nebula Genomics' presence in personalized medicine and securing lower Whole Genome Sequencing prices. The promotions recognize the leadership of Lioi, Karkus, and Miralles in developing ProPhase Diagnostics and expanding its lab services.
ProPhase Labs, Inc. (Nasdaq: PRPH) announced the grant of a stock option to a new employee, consisting of 100,000 shares of common stock. This inducement award was made under Nasdaq Rule 5635(c)(4), not within the company's equity plan. The exercise price is set at $5.76 per share, equal to the stock’s closing price on November 19, 2021. Vesting occurs over four years, starting with 25% on the grant date, and the option has a term of seven years. ProPhase, a diversified biotech firm, focuses on genomics and diagnostic services, including COVID-19 testing.
FAQ
What is the current stock price of ProPhase Labs (PRPH)?
What is the market cap of ProPhase Labs (PRPH)?
What does ProPhase Labs, Inc. do?
What are the main segments of ProPhase Labs' operations?
What services does the Diagnostic Services segment provide?
What products are offered in the Consumer Products segment?
What is the BE-Smart Esophageal Cancer Test?
What recent projects has ProPhase Labs undertaken?
How does ProPhase Labs engage with its investors?
How does ProPhase Labs contribute to healthcare?
